In addition, standard of care for patients with BPH is surgery, and few alternative treatment options are available for those patients, including alpha-blockers, 5α reductase inhibitors (5-ARIs), phosphodiesterase-5 (PDE5) inhibitors, and diuretics, further supporting immunization strategies [26,27]. This evidence concerns the gene PDE5A and benign prostatic hyperplasia.